Insmed is committed to developing therapies that address the needs of patients with serious and rare diseases that are currently overlooked. As part of this effort, we actively conduct clinical trials to advance the development of our product candidates and to better understand their potential benefits and risks.
To learn more about our current clinical trials, including eligibility, locations, and the process for potentially participating in a study, visit www.clinicaltrials.gov in the U.S. or www.clinicaltrialsregister.eu in the EU.
We encourage you to reach out to us with any questions about our clinical trials.
If you have non-cystic fibrosis bronchiectasis (NCFBE), you may be eligible for the ASPEN study
If you have nontuberculous mycobacterial (NTM) lung disease caused by Mycobacterium avium complex (MAC), you may be eligible for the ARISE and ENCORE studies
Insmed Incorporated © 2021 All rights reserved.
Insmed Incorporated © 2021 All rights reserved.
Insmed, ARIKAYCE, Arikares, and PULMOVANCE are trademarks of Insmed Incorporated. All other trademarks are property of their respective owner.
© Insmed 2021. All Rights Reserved.Terms of UsePrivacy Policy